(Q37793824)

23 August 2017

Triple-negative breast cancer: disease entity or title of convenience? (English)

1 reference

triple-negative breast cancer

23 August 2017

0 references

5

Luca Gianni

1 reference

23 August 2017

3

Giuseppe Viale

1 reference

23 August 2017

2

Eric Winer

1 reference

23 August 2017

Lisa Carey

1

1 reference

PubMed ID

20877296

23 August 2017

David Cameron

series ordinal

4

1 reference

PubMed ID

20877296

23 August 2017

language of work or name

English

0 references

publication date

28 September 2010

1 reference

Nature Reviews Clinical Oncology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

12

1 reference

23 August 2017

683-692

1 reference

Molecular alterations in columnar cell lesions of the breast.

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Triple negative tumours: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Triple-negative breast cancer: clinical features and patterns of recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Prognostic markers in triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Refinement of breast cancer classification by molecular characterization of histological special types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

p63: Molecular complexity in development and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Molecular portraits of human breast tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Repeated observation of breast tumor subtypes in independent gene expression data sets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Gene expression profiling of breast cell lines identifies potential new basal markers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Supervised risk predictor of breast cancer based on intrinsic subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

The mammary myoepithelial cell--Cinderella or ugly sister?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Expression of luminal and basal cytokeratins in human breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Subtypes of familial breast tumours revealed by expression and copy number profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

X chromosomal abnormalities in basal-like human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Hallmarks of 'BRCAness' in sporadic cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

The plasticity of human breast carcinoma cells is more than epithelial to mesenchymal conversion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Breast cell invasive potential relates to the myoepithelial phenotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

EGF controls the in vivo developmental potential of a mammary epithelial cell line possessing progenitor properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Typical medullary breast carcinomas have a basal/myoepithelial phenotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Gene expression profiling identifies molecular subtypes of inflammatory breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Integrated profiling of basal and luminal breast cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Triple-negative/basal-like breast cancer: review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Are triple-negative tumours and basal-like breast cancer synonymous?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Gene expression profiling predicts clinical outcome of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Expression of BRCA1 protein in breast cancer and its prognostic significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

BRCA1 dysfunction in sporadic basal-like breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Triple-negative breast cancers are increased in black women regardless of age or body mass index

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Triple negative breast carcinoma is a prognostic factor in Taiwanese women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Epidemiology of basal-like breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Metformin in breast cancer: time for action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Risk factors for triple-negative breast cancer in women under the age of 45 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Triple-negative breast cancer: correlation between MR imaging and pathologic findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Lung metastasis genes couple breast tumor size and metastatic spread.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Breast cancer subtypes and the risk of local and regional relapse.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Cell-type-specific responses to chemotherapeutics in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

The role of BRCA1 in the cellular response to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Platinum-based chemotherapy in triple-negative breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Ixabepilone for the treatment of solid tumors: a review of clinical data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

PARP inhibition: PARP1 and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Identification of molecular apocrine breast tumours by microarray analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.154

Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast.

31 March 2020

1 reference

12 December 2020

Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer

1 reference

12 December 2020

Androgen Receptor Expression in Estrogen Receptor-Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations

1 reference

12 December 2020

Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features

1 reference

12 December 2020

Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status

1 reference

12 December 2020

10.1038/NRCLINONC.2010.154

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20877296